Post-operative Urinary Retention (POUR) Following Thoracic Surgery
Launched by HACKENSACK MERIDIAN HEALTH · Jul 31, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a common problem called post-operative urinary retention, which is when patients have trouble urinating after chest surgery. This issue often affects men over 50 and can make them feel uncomfortable and anxious, leading to longer hospital stays and the need for additional procedures, like inserting a catheter. To help prevent this problem, the trial is testing a medication called Flomax (Tamsulosin), which helps relax the prostate and improve urine flow. Participants will take Flomax daily starting a week before their surgery.
To be eligible for this study, men must be at least 50 years old and have a scheduled minimally invasive thoracic surgery. However, those who are already taking Flomax, have certain medical conditions, or have had prostate surgery in the past cannot join. Participants in the trial can expect to take the medication as directed and will be monitored for any effects on their ability to urinate after surgery. This study is currently recruiting, and it aims to make the recovery process more comfortable for patients undergoing these types of surgeries.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Males
- • ≥50 years old Planned surgical procedure of a minimally invasive thoracic surgical procedure (wedge resection, segmentectomy, lobectomy, pleural biopsy, or pleurodesis) Surgery scheduled more than 3 days from the time of consent
- Exclusion Criteria:
- • Using Flomax already
- • Allergy to Flomax or sulfa drugs
- • Current use of alpha blockers or alpha agonists
- • Resting systolic blood pressure \<100
- • Orthostatic hypotension of \>20mm Hg (millimeters of mercury) Systolic and/or 10mm Hg diastolic pressure from sitting to standing (after 2 minutes of standing) as measured at the time of consent
- • Known diagnosis of congestive heart failure and valvular heart disease
- • History of prostate surgery (prostatectomy, trans-urethral resection)
About Hackensack Meridian Health
Hackensack Meridian Health is a leading healthcare organization based in New Jersey, dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent sponsor of clinical research, Hackensack Meridian Health is committed to fostering collaboration between researchers, healthcare professionals, and patients to develop and evaluate cutting-edge therapies and interventions. With a focus on enhancing health outcomes and addressing pressing medical needs, the organization leverages its extensive network of hospitals, specialty care centers, and research facilities to advance clinical knowledge and contribute to the global body of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hackensack, New Jersey, United States
Hackensack, New Jersey, United States
Patients applied
Trial Officials
Daniel Mansour, MD
Principal Investigator
Hackensack Meridian Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials